Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Histone deacetylases (HDACs) are a family of enzymes that remove acetyl groups from lysine residues on histones and non-histone proteins, leading to chromatin condensation and transcriptional repression. The term "pan-HDAC" refers to agents or inhibitors that target multiple HDAC isoforms across different classes. Inhibition of pan-HDAC results in global hyperacetylation with broad changes in cellular function. They are investigated mainly for oncology indications but also neurological/fibrotic diseases.
Pan-HDAC inhibitors block the activity of multiple or all classical zinc-dependent HDAC isoforms, leading to hyperacetylation of histones and altered gene expression profiles.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Histone Deacetylase (pan) (HDAC).